中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

68 records (took 0.033 seconds)

    SENSING CARDIAC SIGNALS WITH LEADS IMPLANTED IN EPIDURAL SPACE
    11.
    发明申请
    SENSING CARDIAC SIGNALS WITH LEADS IMPLANTED IN EPIDURAL SPACE 有权

    公开(公告)号：US20240374901A1

    公开(公告)日：2024-11-14

    申请号：US18784471

    申请日：2024-07-25

    Applicant: Medtronic, Inc.

    Inventor： Jiashu Li ,  Jeffery Kramer ,  Vinod Sharma

    IPC: A61N1/36 ,  A61B5/00 ,  A61B5/024 ,  A61B5/366

    Abstract: Techniques are disclosed for using a cardiac signal sensed via a plurality of electrodes disposed on one or more leads implanted within an epidural space of a patient to control spinal cord stimulation (SCS) therapy. In one example, an implantable medical device (IMD) senses an electrical signal via a plurality of electrodes disposed on one or more leads implanted within an epidural space of a patient. Processing circuitry determines, from the electrical signal, one or more cardiac features indicative of activity of a heart of the patient. The processing circuitry controls, based on the one or more cardiac features, delivery of SCS therapy to the patient.

    SENSING FOR HEART FAILURE MANAGEMENT
    15.
    发明申请
    SENSING FOR HEART FAILURE MANAGEMENT 有权

    公开(公告)号：US20220323007A1

    公开(公告)日：2022-10-13

    申请号：US17808924

    申请日：2022-06-24

    Applicant: Medtronic, Inc.

    Inventor： Jonathan L. Kuhn ,  James K. Carney ,  Vinod Sharma ,  Shantanu Sarkar ,  Todd M. Zielinski ,  Tommy D. Bennett

    IPC: A61B5/00 ,  A61B5/0205 ,  A61B5/07 ,  A61B5/1455 ,  A61B5/1459 ,  A61B5/287

    Abstract: In some examples, determining a heart failure status includes using an implantable medical device configured for subcutaneous implantation and comprising a plurality of electrodes and an optical sensor. Processing circuitry of a system comprising the device may determine, for a patient, a current tissue oxygen saturation value based on a signal received from the at least one optical sensor, a current tissue impedance value based on a subcutaneous tissue impedance signal received from the electrodes, and a current pulse transit time value based on a cardiac electrogram signal received from the electrodes and at least one of the signal received from the optical sensor and the subcutaneous tissue impedance signal. The processing circuitry may further compare the current tissue oxygen saturation value, current tissue impedance value, and current pulse transit time value to corresponding baseline values, and determine the heart failure status of the patient based on the comparison.

    MEDICAL SYSTEM FOR THERAPY ADJUSTMENT
    16.
    发明申请
    MEDICAL SYSTEM FOR THERAPY ADJUSTMENT 有权

    公开(公告)号：US20220032068A1

    公开(公告)日：2022-02-03

    申请号：US17404542

    申请日：2021-08-17

    Applicant: Medtronic, Inc.

    Inventor： Vinod Sharma

    IPC: A61N1/365 ,  A61N1/372 ,  A61B5/00

    Abstract: Methods and systems for seamless adjustment of treatment are disclosed. A determination can be made as to whether to intervene with a patient's treatment based on data obtained from implantable electrodes and/or non-implantable electrodes. The data from non-implantable electrodes have a correction factor applied to adjust for less accuracy compared to data acquired from implantable electrodes.

    Using biomarker information for heart failure risk computation
    17.
    发明授权
    Using biomarker information for heart failure risk computation 有权

    公开(公告)号：US10517542B2

    公开(公告)日：2019-12-31

    申请号：US14964529

    申请日：2015-12-09

    Applicant: Medtronic, Inc.

    Inventor： Vinod Sharma ,  Eduardo N Warman ,  Yong K Cho ,  Shantanu Sarkar

    IPC: A61B5/00 ,  G16H20/00 ,  G16H50/30 ,  G16H50/20 ,  A61B5/0205 ,  A61B5/044 ,  A61B5/145 ,  G16H15/00 ,  A61B5/046 ,  A61B5/0464 ,  A61B5/053 ,  A61B5/11

    Abstract: Provided is a method, system and/or apparatus for determining prospective heart failure event risk. Acquired from a device memory are a heart failure patient's current and preceding risk assessment periods. Counting detected data observations in the current risk assessment period for a current risk assessment total amount and counting detected data observations in the preceding risk assessment period for a preceding risk assessment period total amount. Associating the current risk assessment and preceding risk assessment total amounts with a lookup table to acquire prospective risk of heart failure (HF) event for the preceding risk assessment period and the current risk assessment period. Employing weighted sums of the prospective risk of the HF event for the preceding risk assessment period and the current risk assessment period to calculate a weighted prospective risk of the HF event for a patient. Displaying on a graphical user interface the weighted prospective risk of the HF event for the patient.

    SENSING FOR HEART FAILURE MANAGEMENT
    18.
    发明申请
    SENSING FOR HEART FAILURE MANAGEMENT 审中-公开

    公开(公告)号：US20190336076A1

    公开(公告)日：2019-11-07

    申请号：US15969369

    申请日：2018-05-02

    Applicant: Medtronic, Inc.

    Inventor： Jonathan L. Kuhn ,  James K. Carney ,  Vinod Sharma ,  Shantanu Sarkar ,  Todd M. Zielinski ,  Tommy D. Bennett

    IPC: A61B5/00 ,  A61B5/0205 ,  A61B5/042 ,  A61B5/07 ,  A61B5/1455 ,  A61B5/1459

    Abstract: In some examples, determining a heart failure status includes using an implantable medical device configured for subcutaneous implantation and comprising a plurality of electrodes and an optical sensor. Processing circuitry of a system comprising the device may determine, for a patient, a current tissue oxygen saturation value based on a signal received from the at least one optical sensor, a current tissue impedance value based on a subcutaneous tissue impedance signal received from the electrodes, and a current pulse transit time value based on a cardiac electrogram signal received from the electrodes and at least one of the signal received from the optical sensor and the subcutaneous tissue impedance signal. The processing circuitry may further compare the current tissue oxygen saturation value, current tissue impedance value, and current pulse transit time value to corresponding baseline values, and determine the heart failure status of the patient based on the comparison.

    DETERMINING PROSPECTIVE RISK OF HEART FAILURE HOSPITALIZATION
    19.
    发明申请
    DETERMINING PROSPECTIVE RISK OF HEART FAILURE HOSPITALIZATION 审中-公开

    公开(公告)号：US20190110756A1

    公开(公告)日：2019-04-18

    申请号：US16218694

    申请日：2018-12-13

    Applicant: Medtronic, Inc.

    Inventor： Vinod Sharma ,  Eduardo N. Warman ,  Karen J. Kleckner

    IPC: A61B5/00 ,  A61B5/044 ,  A61B5/0432 ,  A61B5/145 ,  G16H50/30 ,  G16H50/20 ,  G16H15/00 ,  A61B5/0205

    Abstract: A method of operation of a medical device system for determining prospective heart failure hospitalization risk. The method includes measuring one or more data observations via one or more electrodes of an implanted medical device disposed in a patient's body. The data observations are stored into memory of the implantable medical device of a patient. The data observations are transmitted to an external device. The processor of the external device parses the data observations into one or more evaluation periods. Using the number of observations in one or more evaluation periods, a look up table, stored into memory of the external device, is accessed. The look up table associates prospective heart failure hospitalization risk with the data observations noted in the evaluation period. One or more embodiments involve a weighted prospective heart failure hospitalization risk for the set of evaluation periods. The prospective heart failure hospitalization is then displayed on the graphical user interface.

Patent Agency Ranking